A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 189
Summary
- Conditions
- Advanced Gastric Adenocarcinoma
- Advanced Urothelial Carcinoma
- Metastatic Colorectal Adenocarcinoma
- Metastatic Renal Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02599324
- Collaborators
- Not Provided
- Investigators
- Study Director: Jim Dean, M.D. Pharmacyclics, an AbbVie Company